Skip to main content
. 2014 Dec 10;12:340. doi: 10.1186/s12967-014-0340-9

Figure 7.

Figure 7

Dose- and time-dependent effects of LCI699 on ACTH-stimulated aldosterone, cortisol and precursors (human study, multiple-dose phase). Mean plasma concentrations of (A) aldosterone, (B) cortisol, (C) the aldosterone precursor 11-deoxycorticosterone (11-DOC), and (D) the cortisol precursor 11-deoxycortisol, at 0, 30 and 60 min after adrenocorticotropic hormone (ACTH) administration at baseline (Day –2) and on Days 6 and 13 of once-daily treatment with LCI699 (0.5, 1 or 3 mg), eplerenone (100 mg) or placebo in healthy human volunteers. Values are means. Number of evaluable subjects for LCI699 0.5, 1, 3 mg, eplerenone and placebo were (Day -2 and 6) n = 12, 12, 12, 10 and 9 respectively, and (Day 13) n = 12, 12, 9, 8 and 8 respectively. *P < 0.05, P < 0.01, P < 0.001 vs placebo.